Several studies [17, 32, 78] demonstrated no differences in IL‐17 BALF levels between BOS and/or RAS patients and stable LTR, although elevated levels at 6–12 months post‐transplant were predictive of early BOS in a study by Fisichella et al. [17] Similarly, no difference was seen in stable LTR with high versus low neutrophils counts [41]. The gene discussed is IL17A; the disease is Buschke-Ollendorff syndrome.